ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Arcutis Biotherapeutics and Huadong Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Arcutis Biotherapeutics×Huadong Medicine×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaArcutis BiotherapeuticsHuadong Medicine
studies on the registry4,1972662
open to participants now298246
phase 3 studies under way200112
reach primary completion within a year168016
programswith a study of their own in two years119+5 named only317

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaArcutis BiotherapeuticsHuadong Medicine
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Arcutis Biotherapeutics: 1 of its 3 programs at phase 1

  1. ARQ-234phase 1
33%

Huadong Medicine: 7 of its 17 programs at phase 1

  1. HDM2005phase 1
  2. HDM2020phase 1
  3. HDM2006phase 1
  4. HDM2012phase 1
  5. HDM2024phase 1

and 2 more — sign in to see them all

41%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
00%

Huadong Medicine: 1 of its 17 programs at phase 2

  1. HDM2017phase 2
6%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Arcutis Biotherapeutics: 2 of its 3 programs at phase 3

  1. Roflumilastphase 3
  2. ARQ-154phase 3
67%

Huadong Medicine: 8 of its 17 programs at phase 3

  1. HDM1002phase 3
  2. HDM1005phase 3
  3. DR10624phase 3
  4. Roflumilastphase 3
  5. HDM1702phase 3

and 3 more — sign in to see them all

47%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%

Huadong Medicine: 1 of its 17 programs at approved, new studies

  1. janagliflozinapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Arcutis Biotherapeutics0 readouts · 0 phase 3············
Huadong Medicine9 readouts · 2 phase 3·

Huadong Medicine, Dec ’26: 2 programs whose next study reaches primary completion

  1. HDM1005phase 3 · Dec 1 · NCT07502001
  2. HDM2017phase 2 · Dec 31 · NCT07274085

Huadong Medicine, Jan ’27: 1 program whose next study reaches primary completion

  1. HDM2020phase 1 · Jan 31 · NCT07638891

Huadong Medicine, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HDM1002phase 3 · Feb 16 · NCT07082114
·

Huadong Medicine, Apr ’27: 1 program whose next study reaches primary completion

  1. HDM2024phase 1 · Apr 15 · NCT07539285
·

Huadong Medicine, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Roflumilastphase 3 · Jun 30 · NCT07683806

Huadong Medicine, Jul ’27: 1 program whose next study reaches primary completion

  1. HDM2005phase 1 · Jul 1 · NCT07004296

Huadong Medicine, Aug ’27: 1 program whose next study reaches primary completion

  1. Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Lenphase 1 · Aug 10 · NCT07697339
·

Huadong Medicine, Oct ’27: 1 program whose next study reaches primary completion

  1. HDM2012phase 1 · Oct 0 · NCT07100249
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Arcutis Biotherapeutics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Huadong Medicine

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaArcutis BiotherapeuticsHuadong Medicine
Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Arcutis Biotherapeutics in Asthma: 1 program

  1. Roflumilastphase 3

Their studies: Arcutis Biotherapeutics’ studies of Asthma in search

Huadong Medicine in Asthma: 1 program

  1. Roflumilastphase 3

Their studies: Huadong Medicine’s studies of Asthma in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Arcutis Biotherapeutics in Diabetes Mellitus, Type 2: 1 program

  1. Roflumilastphase 3

Their studies: Arcutis Biotherapeutics’ studies of Diabetes Mellitus, Type 2 in search

Huadong Medicine in Diabetes Mellitus, Type 2: 5 programs

  1. HDM1002phase 3
  2. HDM1005phase 3
  3. Roflumilastphase 3
  4. HDG1901phase 3
  5. janagliflozinapproved, new study

Their studies: Huadong Medicine’s studies of Diabetes Mellitus, Type 2 in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Arcutis Biotherapeutics in Pulmonary Disease, Chronic Obstructive: 1 program

  1. Roflumilastphase 3

Their studies: Arcutis Biotherapeutics’ studies of Pulmonary Disease, Chronic Obstructive in search

Huadong Medicine in Pulmonary Disease, Chronic Obstructive: 1 program

  1. Roflumilastphase 3

Their studies: Huadong Medicine’s studies of Pulmonary Disease, Chronic Obstructive in search

Dermatitis, Atopicall three · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Arcutis Biotherapeutics in Dermatitis, Atopic: 2 programs

  1. Roflumilastphase 3
  2. ARQ-234phase 1

Their studies: Arcutis Biotherapeutics’ studies of Dermatitis, Atopic in search

Huadong Medicine in Dermatitis, Atopic: 2 programs

  1. Roflumilastphase 3
  2. betamethasone dipropionatephase 3

Their studies: Huadong Medicine’s studies of Dermatitis, Atopic in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Huadong Medicine in Carcinoma, Non-Small-Cell Lung: 1 program

  1. HDM2020phase 1

Their studies: Huadong Medicine’s studies of Carcinoma, Non-Small-Cell Lung in search

Obesity2 of 3 · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

–

Huadong Medicine in Obesity: 3 programs

  1. HDM1002phase 3
  2. HDM1005phase 3
  3. HDM1702phase 3

Their studies: Huadong Medicine’s studies of Obesity in search

Multiple Myeloma2 of 3 · compare here–

Huadong Medicine in Multiple Myeloma: 1 program

  1. pamlectabart tismanitinphase 1

Their studies: Huadong Medicine’s studies of Multiple Myeloma in search

Psoriasis2 of 3 · compare here–

Arcutis Biotherapeutics in Psoriasis: 2 programs

  1. Roflumilastphase 3
  2. ARQ-154phase 3

Their studies: Arcutis Biotherapeutics’ studies of Psoriasis in search

Huadong Medicine in Psoriasis: 3 programs

  1. Roflumilastphase 3
  2. betamethasone dipropionatephase 3
  3. calcipotrienephase 3

Their studies: Huadong Medicine’s studies of Psoriasis in search

Lymphoma, Mantle-Cell2 of 3 · compare here

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

–

Huadong Medicine in Lymphoma, Mantle-Cell: 2 programs

  1. HDM2005phase 1
  2. Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Lenphase 1

Their studies: Huadong Medicine’s studies of Lymphoma, Mantle-Cell in search

Overweight2 of 3 · compare here

AstraZeneca in Overweight: 1 program

  1. lenbelintidephase 3

Their studies: AstraZeneca’s studies of Overweight in search

–

Huadong Medicine in Overweight: 2 programs

  1. HDM1002phase 3
  2. HDM1005phase 3

Their studies: Huadong Medicine’s studies of Overweight in search

Colorectal Neoplasms2 of 3 · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

–

Huadong Medicine in Colorectal Neoplasms: 1 program

  1. HDM2017phase 2

Their studies: Huadong Medicine’s studies of Colorectal Neoplasms in search

Lymphoma2 of 3 · compare here

AstraZeneca in Lymphoma: 1 program

  1. PRMT5 Inhibitor AZD3470phase 2

Their studies: AstraZeneca’s studies of Lymphoma in search

–

Huadong Medicine in Lymphoma: 1 program

  1. HDM2005phase 1

Their studies: Huadong Medicine’s studies of Lymphoma in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Arcutis Biotherapeutics 1 of 3 · Huadong Medicine 5 of 17 programs (35 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).